Sialic Acid Analysis of Biotherapeutic Glycoproteins Using AdvanceBio Sialic Acid Profiling and Quantitation Kit and LC/FLD/MS

Significance of the Topic

The terminal sialic acids on biotherapeutic glycoproteins play a critical role in determining pharmacokinetics, immunogenicity, and biological activity. Quantitative and qualitative profiling of Neu5Ac and Neu5Gc is essential for ensuring safety and efficacy of monoclonal antibodies and fusion proteins, as Neu5Gc can elicit immune responses in humans.

Objectives and Study Overview

This guide presents a standardized workflow for release, labeling, separation, and detection of sialic acids using the Agilent AdvanceBio Sialic Acid Profiling and Quantitation kit coupled with LC/FLD or LC/MS. The aim is to provide users with comprehensive consumables ordering information and optimized conditions for accurate profiling and quantitation in biotherapeutic samples.

Methodology and Used Instrumentation

The workflow consists of four main steps:

• Sialic acid release: incubate glycoprotein with acid reagent at 80 °C for 2 hours.
• DMB labeling: derivatize released sialic acids at 50 °C for 3 hours using 1,2-diamino-4,5-methylenedioxybenzene.
• Reverse-phase LC separation: employ an Agilent InfinityLab Poroshell 120 EC-C18 column with a rapid 10-minute gradient.
• Detection and quantitation: detect fluorescent derivatives via FLD (λEX 373 nm/λEM 448 nm) or specific ions by high-resolution LC/Q-TOF MS.

Used Instrumentation:

• Agilent 1290 Infinity II UHPLC with InfinityLab Poroshell 120 EC-C18 columns.
• Agilent 6545XT AdvanceBio LC/Q-TOF for high-resolution ESI-MS.
• Thermal cycler or dry block heaters for controlled incubations.
• OpenLab CDS and MassHunter software for data analysis and quantitation.

Main Results and Discussion

Chromatograms demonstrate baseline separation of seven DMB-labeled sialic acid species with consistent retention times. Fluorescence and extracted ion chromatograms confirm detection of Neu5Ac, Neu5Gc, and their acetylated variants. Quantitative reproducibility is indicated by low %CV values (<2%) across the reference panel. The method reliably measures 1 to 2000 pmol of sialic acids per well, covering both profiling and absolute quantitation.

Benefits and Practical Applications

This streamlined approach offers:

• Complete sample preparation in approximately 5 hours.
• High sensitivity for low-sialylated proteins such as monoclonal antibodies.
• Automatable 96-well plate format with no glass ampoules and minimal sample drying.
• Compatibility with both FLD and MS detection for flexible application in QA/QC and research laboratories.

Future Trends and Possibilities

Emerging directions include:

• Automation of sample preparation to increase throughput in large-scale bioprocessing.
• Integration with multi-attribute method platforms for comprehensive glycan profiling.
• Development of new labels for enhanced MS sensitivity and multiplexed analysis.
• Application to novel glycoprotein modalities such as bispecifics and ADCs.

Conclusion

The AdvanceBio Sialic Acid Profiling and Quantitation workflow combines robust sample preparation, rapid chromatographic separation, and sensitive detection to deliver reliable analysis of biotherapeutic sialylation. The comprehensive consumables guide facilitates straightforward implementation and supports consistent, high-quality data across laboratories.

References

1. Antibody Glycosylation and its Impact on the Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies and Fc Fusion Proteins Journal of Pharmaceutical Sciences 2015, 104(6), 1866–1884
2. An Improved Workflow for Profiling and Quantitation of Sialic Acids in Biotherapeutics Agilent publication 5994-2352EN, 2020
3. AdvanceBio Sialic Acid Profiling and Quantitation Kit User Manual 5994-2800EN, Agilent Technologies 2021